Mark Toshner

Oct 3, 2024 | erj.ersjournals.com | Mark Toshner

FootnotesConflict of interest: M. Toshner declares relationships with Janssen Pharmaceuticals Inc., Merck Sharp & Dohme UK Ltd, and Apollo Therapeutics that include consulting and/or advisory work. E.M.D.D. De Bie has no potential conflicts of interest to disclose. Support statement: M. Toshner is supported by the NIHR Cambridge Biomedical Research Centre. E.M.D.D. De Bie is supported by the Gates Cambridge Trust (Gates grant number OPP1144).

Jun 1, 2023 | nature.com | Mark Toshner

Sotatercept is the first successful therapy to make it through phase 3 to regulatory submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory mechanisms. The phase 3 STELLAR study of sotatercept treatment challenges established thinking on pulmonary vascular remodeling and offers patients hope for a step change in outcomes.